{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:14:33Z","timestamp":1780557273107,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.vaccine.2016.04.012","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T04:15:32Z","timestamp":1460607332000},"page":"2562-2569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Identification of GLA\/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits"],"prefix":"10.1016","volume":"34","author":[{"given":"Darren S.","family":"Heeke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8257-5515","authenticated-orcid":false,"given":"Jennifer C.","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7864-803X","authenticated-orcid":false,"given":"Jason D.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.04.012_bib0180","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.micinf.2004.04.014","article-title":"The immune response to Epstein\u2013Barr virus","volume":"6","author":"Callan","year":"2004","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0185","doi-asserted-by":"crossref","first-page":"107fs7","DOI":"10.1126\/scitranslmed.3002878","article-title":"Epstein\u2013Barr virus: an important vaccine target for cancer prevention","volume":"3","author":"Cohen","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0190","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","article-title":"Cellular responses to viral infection in humans: lessons from Epstein\u2013Barr virus","volume":"25","author":"Hislop","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0195","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jis646","article-title":"Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein\u2013Barr virus infection in university students","volume":"207","author":"Balfour","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0200","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1128\/CMR.00044-10","article-title":"Progress and problems in understanding and managing primary Epstein\u2013Barr virus infections","volume":"24","author":"Odumade","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0205","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0092-8674(87)90216-9","article-title":"Epstein\u2013Barr virus gp350\/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis","volume":"50","author":"Tanner","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0210","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1073\/pnas.77.5.2979","article-title":"Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein\u2013Barr virus identifies a membrane antigen and a neutralizing antigen","volume":"77","author":"Hoffman","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0215","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein\u2013Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0220","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein\u2013Barr virus vaccine in healthy adults","volume":"25","author":"Moutschen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/eji.201141855","article-title":"A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo","volume":"42","author":"Pantel","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0230","doi-asserted-by":"crossref","first-page":"e13677","DOI":"10.1371\/journal.pone.0013677","article-title":"A synthetic adjuvant to enhance and expand immune responses to influenza vaccines","volume":"5","author":"Coler","year":"2010","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.012_bib0235","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/1547691X.2012.708366","article-title":"How aluminum adjuvants could promote and enhance non-target IgE synthesis in a genetically-vulnerable sub-population","volume":"10","author":"Terhune","year":"2012","journal-title":"J Immunotoxicol"},{"issue":"48","key":"10.1016\/j.vaccine.2016.04.012_bib0240","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1016\/j.vaccine.2015.10.024","article-title":"Identification of the critical attribute(s) of EBV gp350 antigen required for elicitation of a neutralizing antibody response in vivo","volume":"33","author":"Servat","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0245","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.virol.2009.06.013","article-title":"Human antibody titers to Epstein\u2013Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay","volume":"391","author":"Sashihara","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0250","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/imm.12411","article-title":"CD11c+ CD103+ cells of Mycobacterium tuberculosis-infected C57BL\/6 but not of BALB\/c mice induce a high frequency of interferon-gamma- or interleukin-17-producing CD4+ cells","volume":"144","author":"Sergio","year":"2015","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0255","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00436-014-3764-5","article-title":"Comparison of dynamic expressions of Tim-3 and PD-1 in the brains between toxoplasmic encephalitis-resistant BALB\/c and -susceptible C57BL\/6 mice","volume":"113","author":"Wu","year":"2014","journal-title":"Parasitol Res"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2016.04.012_bib0260","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000350367","article-title":"Interleukin-5 plays a key role in mouse strain-dependent susceptibility to contact hypersensitivity through its effects on initiator B cells","volume":"161","author":"Itakura","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0265","first-page":"247","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0270","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.vaccine.2009.10.051","article-title":"Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge","volume":"28","author":"Faul","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0275","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1038\/cti.2014.27","article-title":"Epstein\u2013Barr virus vaccines","volume":"4","author":"Cohen","year":"2015","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0280","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1128\/JVI.65.2.996-1001.1991","article-title":"Epstein\u2013Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity","volume":"65","author":"Khyatti","year":"1991","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0285","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1084\/jem.20051287","article-title":"Control of Epstein\u2013Barr virus infection in vitro by T helper cells specific for virion glycoproteins","volume":"203","author":"Adhikary","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0290","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1128\/JVI.65.7.3821-3828.1991","article-title":"Identification of two T-cell epitopes on the candidate Epstein\u2013Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones","volume":"65","author":"Wallace","year":"1991","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0295","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.4049\/jimmunol.162.5.3063","article-title":"EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350\/gp85 CTL epitopes for vaccine design","volume":"162","author":"Khanna","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0300","first-page":"171","article-title":"First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen","volume":"84","author":"Gu","year":"1995","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0305","doi-asserted-by":"crossref","first-page":"e16333","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"Coler","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0310","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2051013613480144","article-title":"Working together: interactions between vaccine antigens and adjuvants","volume":"1","author":"Fox","year":"2013","journal-title":"Ther Adv Vaccines"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0315","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1477-3155-11-43","article-title":"Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity","volume":"11","author":"Fung","year":"2013","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0320","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.3390\/v6114358","article-title":"Anti-glycoprotein g antibodies of herpes simplex virus 2 contribute to complete protection after vaccination in mice and induce antibody-dependent cellular cytotoxicity and complement-mediated cytolysis","volume":"6","author":"Gorander","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0325","doi-asserted-by":"crossref","first-page":"19396","DOI":"10.1073\/pnas.1014515107","article-title":"FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo","volume":"107","author":"Nimmerjahn","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0330","doi-asserted-by":"crossref","first-page":"17585","DOI":"10.1073\/pnas.1207308109","article-title":"Adjuvant solution for pandemic influenza vaccine production","volume":"109","author":"Clegg","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.vaccine.2016.04.012_bib0335","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/IAI.01108-12","article-title":"Full-length P. falciparum circumsporozoite protein administered with poly-ICLC or GLA\/SE elicits potent antibody and CD4+ T cell immunity and protection in mice","volume":"81","author":"Kastenmuller","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0340","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2249.2008.03699.x","article-title":"Detailed analysis of Epstein\u2013Barr virus-specific CD4+ and CD8+ T cell responses during infectious mononucleosis","volume":"153","author":"Scherrenburg","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2016.04.012_bib0345","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/blood-2009-11-252437","article-title":"EBV meets its match","volume":"115","author":"Fox","year":"2010","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2016.04.012_bib0350","doi-asserted-by":"crossref","first-page":"B194","DOI":"10.1016\/j.vaccine.2012.09.041","article-title":"The need and challenges for development of an Epstein\u2013Barr virus vaccine","volume":"31","author":"Cohen","year":"2013","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16301402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16301402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T16:18:11Z","timestamp":1692289091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16301402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":35,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0264410X16301402"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.012","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of GLA\/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}